Michel van Harten
CEO

myTomorrows provides a cloud‑based platform that aggregates clinical trial and expanded access data, using AI to pre‑screen patients and match them with suitable treatment options. The service connects patients, physicians, and trial sites through secure, compliant tools and dedicated patient navigators, while offering BioPharma companies targeted recruitment and real‑world data collection.
Raised to date
$10.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.


CEO
Patients with serious or rare diseases often struggle to find and access clinical trials or expanded access programs because relevant information is scattered across multiple registries, and navigating eligibility, referrals, and regulatory requirements is complex and time‑consuming.
myTomorrows offers a cloud‑based platform that aggregates trial and expanded access data from trusted registries and applies AI‑driven pre‑screening to match patients’ medical profiles with suitable options. The service connects patients, their physicians, and trial sites through a secure, GDPR‑compliant environment, and assigns multilingual patient navigators to guide users through referral, enrollment, and compassionate‑use processes. For healthcare professionals, the platform provides rapid search, eligibility checks, and direct communication tools with trial sites, all at no cost. BioPharma partners benefit from targeted patient recruitment, end‑to‑end expanded access program management, and real‑world data collection, all supported by ISO 27001, SOC 2, and GMP‑aligned quality systems.
Primary users are patients with serious or rare diseases and their caregivers, as well as treating physicians seeking timely trial or EAP options; BioPharma companies and CROs use the platform for patient recruitment, EAP management, and RWD generation.